These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2475652)

  • 21. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
    Matsuura Y; Nakamura H; Kogure K; Fukazawa M; Okuyama Y; Kawano E; Ishii A; Nishimura M; Hashimoto S; Oh H
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):237-41. PubMed ID: 8311495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).
    Cavalli F
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):33-6. PubMed ID: 3975656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
    Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
    Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
    Niitsu N; Hara A; Umeda M; Shirai T
    Rinsho Ketsueki; 1993 Jul; 34(7):829-34. PubMed ID: 7689661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of MIME salvage regimen for recurrent or refractory lymphoma.
    Cabanillas F; Hagemeister FB; McLaughlin P; Velasquez WS; Riggs S; Fuller L; Smith T
    J Clin Oncol; 1987 Mar; 5(3):407-12. PubMed ID: 3819806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MECHOP-BM chemotherapy in the treatment of non Hodgkin's lymphoma].
    Inoue N; Miyazaki E; Okada M; Wada H; Nishimura T; Tamura S; Fujimori Y; Okamoto T; Takemoto Y; Kosaki M
    Rinsho Ketsueki; 1994 Jun; 35(6):535-40. PubMed ID: 8078187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):626-9. PubMed ID: 3827258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vindesine, etoposide (VP-16), and prednisolone (VEP) in relapsed patients with grade II non-Hodgkin's lymphoma.
    Hancock BW
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):26-8. PubMed ID: 3975655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma].
    Takasu S; Wakabayashi T; Kajita Y; Hatano N; Hatano H; Usui T; Kinoshita T; Yoshida J
    No Shinkei Geka; 2000 Sep; 28(9):789-94. PubMed ID: 11025878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy].
    Okamoto M
    Rinsho Ketsueki; 1998 Feb; 39(2):111-2. PubMed ID: 9545814
    [No Abstract]   [Full Text] [Related]  

  • 38. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
    Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
    Cancer Treat Rep; 1987 May; 71(5):475-8. PubMed ID: 3567972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic factors of follicular lymphoma treated with combination chemotherapy].
    Niitsu N; Umeda M
    Rinsho Ketsueki; 1997 Jun; 38(6):496-504. PubMed ID: 9248325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
    Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
    Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.